Senseonics(NYSEMKT) SENS

Senseonics makes implantable glucose monitoring systems for people with diabetes. Its products help users track blood sugar levels in real time. These systems aim to reduce the hassle of frequent finger-prick tests.

Gadgets That Keep Tabs: Products and Services

• Eversense E3: Implantable sensor for continuous glucose monitoring, lasting up to six months; main product in the U.S.
• Eversense 365: New implantable sensor with a one-year lifespan, launched in the U.S. in late 2024; expanding to Europe in 2026.
• Eversense XL: 180-day sensor, previously sold in Europe and the Middle East.
• Gemini (in development): Next-generation sensor aiming for both continuous and flash glucose monitoring.
• Eon Care Network: Service for sensor insertion and user training, supporting healthcare providers and patients.

Growth Spurts and Bold Moves

• FDA approved Eversense 365 in September 2024; U.S. launch followed in Q4 2024.
• CE Mark for Eversense 365 in January 2026, enabling European launch in H2 2026.
• Transitioned U.S. and European commercial operations from Ascensia to Senseonics in January 2026.
• Expanded direct-to-consumer marketing and digital outreach in 2025.
• Partnered with Sequel Med Tech to integrate Eversense 365 with automated insulin delivery systems.

What Makes Senseonics Stand Out

Senseonics offers the longest-lasting implantable glucose sensors, reducing the need for frequent replacements. Its direct sales and care network support a growing user base in the U.S. and Europe. The company’s focus on integration with automated insulin systems sets it apart from traditional glucose monitoring providers.

Five Things You Need to Know

• Revenue was $35.3 million in 2025, up 56.9% from 2024.
• Gross margin improved to 44.7% in 2025, from 2.4% in 2024.
• U.S. sales made up 79.2% of 2025 revenue; international sales were 20.8%.
• Operating loss was $(68.3) million in 2025, improving from $(74.8) million in 2024.

Bottom Line

Senseonics has shifted from distributor-led to direct sales, expanded its product line, and improved margins. The company continues to adapt through innovation and new partnerships in a competitive market.